Last Updated on April 21, 2021 by The Health Master
Sun Pharma, Alembic recall products in the US market
New Delhi: Leading drug makers Sun Pharma and Alembic Pharmaceuticals are recalling different products in the US market, the world’s largest market for medicines.
Sun Pharma recall
As per the latest Enforcement Report by the US Food and Drug Administration (USFDA), US-based unit of Sun Pharma is recalling 91,211 pre-filled syringes of Ganirelix Acetate injection due to “failed impurities / degradation specifications“.
The affected lot has been manufactured at Sun Pharma’s Halol plant in Gujarat and distributed in the US by Ferring Pharmaceuticals Inc, the report stated.
The drug major initiated the recall on March 15 this year and the USFDA has classified it as Class II action, which is undertaken in a situation “in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote”.
Also read:
Gilead gets USFDA not to treat metastatic urothelial cancer
NATCO gets tentative USFDA nod for Ibrutinib tablets
First AI device to help detect colon cancer gets USFDA nod
Aleor gets tentative USFDA nod for drug for topical treatment
Zydus Cadila gets final USFDA nod for drug to treat High…
Dr Reddy’s launch generic Sapropterin Dihydrochloride Powder for Oral Solution in…
Ganirelix Acetate Injection is used in assisted reproduction to control ovulation.
Princeton (New Jersey) based Sun Pharmaceutical Industries Inc is also recalling 2,520 bottles of diabetes drug, Metformin HCl Extended-Release tablets, in the US market.
As per the USFDA, the drug firm is recalling the affected lot, which is also manufactured in a Gujarat-based plant, for “failed moisture limits: Out of specification for water content”.
The company initiated the recall on March 25 and the US health regulator has placed the action under Class III.
As per the USFDA, a class III recall is initiated in a “situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences”.
Alembic recall
Similarly, Alembic Pharmaceuticals is recalling 12,288 bottles of Telmisartan Tablets (USP 20 mg, 30-count bottles) in the US market. As per the USFDA, the drug firm is recalling the product for “label mix up”.
The affected lot has been produced at the company’s Panelav based plant in Gujarat and then shipped to Bridgewater (New Jersey) based Alembic Pharmaceuticals, Inc.
Telmisartan Tablets are mainly indicated for the treatment of hypertension.
According to industry estimates, the US generic drug market was estimated to be around USD 115.2 billion in 2019.
Also read:
New Regulatory Regime for 8 Medical Devices under D&C Act
Latest Circulars, Notices & Guidelines: CDSCO, DCGI
New price of Remdesivir injection, prices reduced by 7 companies: NPPA
Retail and Wholesale Pharmacies rises in Odisha
Health Parliament urges PM to declare National Health Emergency in the…
NPPA directs reduction in Remdesivir price
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
